Glythera is an emerging biotechnology company specializing in the development of next generation biotherapeutics through the application of its advanced proprietary conjugation and glycosylation technologies.
Located in the North East of the UK with its dedicated bioprocessing and chemistry development laboratories at Newcastle University, Glythera is positioned as a critical partner in any development program centred on its PermaLink™ and PermaCarb™ technologies.
Our PermaLink™ platform supports highly selective site specific conjugation whilst demonstrating significantly increased stability with our core focus being in the development of enhanced Antibody Drug Conjugates and bi-specifics.
Glythera’s PermaCarb™ technology allows direct substitution of endogenous glycan’s or correction of micro-heterogeneity using stable analogues to improve bioavailability and efficacy and has been demonstrated in a range of next generation biotherapeutics.
Our Mission is to enable improved clinical regimes through the creation of the next generation of safe, efficacious biotherapeutic products in oncology and therapeutic indications.